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We tested the efficacy of three selective agonists of
prostaglandin E2 (PGE2) receptor, EP2 (CP-536,745-01), EP2/4
(CP-043,305-02), and EP4 (CP-044,519-02), in two models of
acute and chronic kidney failure. In the nephrotoxic mercury
chloride (HgCl2) rat model of acute kidney failure systemically
administered EP4 agonist reduced the serum creatinine
values and increased the survival rate. Although the EP2
or the EP2/4 agonist did not change the serum creatinine
values, the EP2 receptor agonist increased the survival rate.
Histological evaluation of kidneys from EP4-treated rats
indicated less proximal tubular necrosis and less apoptotic
cells. In a rat model of chronic renal failure, the three receptor
agonists decreased the serum creatinine and increased the
glomerular filtration rate at 9 weeks following therapy.
Kidneys treated with the EP4 agonist had less glomerular
sclerosis, better preservation of proximal and distal tubules
and blood vessels, increased convoluted epithelium
proliferation and less apoptotic cells. Nephrectomy had no
influence on the expression of the EP4 receptor, whereas EP2
receptor expression was reduced by 50% and then corrected
following treatment with EP2 and EP2/4 receptor agonists.
These findings suggest that PGE2 has an important role in
acute kidney failure via the EP4 receptor, whereas in chronic
kidney failure both EP2 and EP4 receptors are equally
important in preserving the progression of chronic kidney
failure. Thus, agonism of EP2 and EP4 receptors may provide
a basis for treating acute and chronic kidney failure.
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Acute and chronic renal failures are directly responsible for
high rate of mortality, significant morbidity, and high
medical costs.1,2 Acute renal failure (ARF) is a very morbid
and costly disorder with a severe proportion of patients
progressing to end-stage renal disease requiring dialysis.
Despite the advances of supportive care, the mortality has
remained high (40–80%).3 Although the damaged kidney is
capable of complete repair and regeneration after acute
injury, the successful treatment of patients with ARF who
require dialysis remains one of the greatest challenges facing
nephrology today.4,5 The mechanisms controlling the cascade
of cellular migration, growth, and proliferation undoubtedly
comprise a number of autocrine and paracrine growth
factors.6,7 Several novel compounds have proved effective in
the treatment of experimental ARF, but there has been little
success in human clinical trials, including synthetic atrial
natriuretic peptide, recombinant human insulin-like growth
factor-1, calcium channel antagonists, thyroxine, and endo-
thelin receptor antagonists.8
Chronic renal failure (CRF) is another entity, which
progresses to end-stage renal failure, independently of the
initial pathogenic mechanism. The early stages of renal injury
involve compensatory renal growth associated with cellular
hypertrophy and hyperplasia.9,10 The infiltration of platelets,
lymphocytes, and monocytes into the glomeruli and inter-
stitium causes the progression of renal scarring.11,12 This
scarring process then leads to a progressive damage of
glomerular and tubular cells, and eventually causes glome-
rular sclerosis and tubular atrophy. In end-stage renal
disease, renal cells are replaced with fibrous tissue contribut-
ing to the sclerotic changes observed in the glomeruli and the
interstitium.11,12 When the glomerular filtration rate (GFR)
declines to less than 10% of normal values (5–10 ml/min),
the renal failure will rapidly progress to cause death unless
the patient receives renal replacement therapy (i.e. chronic
hemodialysis, continuous peritoneal dialysis, or kidney trans-
plantation) or alternatively a therapy that delays the progres-
sion of the CRF.
At present, there is no specific therapy for chronic renal
disease, and treatment with growth factors may ameliorate
the progression of the kidney disease.13 A potential treatment
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for ARF and CRF could be PGE2 which has been shown to
have multiple biological effects in many tissues including
kidney. PGE2 plays a major role in the normal renal
physiology including production of renin, regulation of
GFR, and tubular re-absorption of salt and water.14 Similarly,
in disease states such as diabetic nephropathy, PGE2 synthesis
is elevated. PGE2 plays an important role in maintaining
the blood flow especially during conditions of enhanced
vasoconstrictor activity. Furthermore, PGE2 inhibits prolif-
eration of cultured mesangial cells in vitro,15 and given the
diversity of PGE2 actions in the kidney it is attractive to
speculate a therapeutic role for PGE2 in chronic and/or acute
kidney failure. However, owing to side effects that include
diarrhea, lethargy, and flushing, PGE2 is an unacceptable
therapeutic option.
The pharmacological activity of PGE2 is carried out via
four different cell surface receptor subtypes: EP1, EP2, EP3,
and EP4. Of these four receptors, three are involved in
modulation of cyclic adenosine 50-monophosphate (cAMP)
levels (EP2 and EP4 increase cAMP levels, EP3 reduces cAMP
levels). The fourth receptor, EP1, is involved in regulating
intracellular calcium levels. All four of the EP receptors have
been localized in the kidney and are responsible for distinct
actions of PGE2. The EP1, EP3, and EP4 receptors are present
in the collecting duct. EP4 has also been shown to be
expressed in the glomerulus and EP2 mRNA has been
localized to the outer and inner medulla of the rat kidney.16,17
Despite the well-known activities of PGE2 in maintaining the
kidney function and localization of various prostanoid
receptors in the kidney, the precise role of their agonists
or antagonists as therapeutic options remains poorly under-
stood. Recently, an EP1 selective antagonist has been
demonstrated to be effective in prevention of diabetic
nephropathy in a streptozotocin-induced rat model.18 We
initiated a discovery effort to identify the role of EP2 and EP4
receptor-selective agonists in rat models of acute and chronic
kidney disease.
In the present study, we have used three different selective
agonists of the PGE2 receptors to assess the ability of agonists
of receptor subtypes to treat rats with acute and chronic renal
failure. Of the three receptor-specific agonists tested, CP-
043,305-02 was selective for both the EP2 and EP4 receptors,
CP-044,519-02 is an EP4-specific agonist, and CP-536,745-01
is an EP2-specific agonist. In this report, we show that CP-
044,519-02, a highly selective and potent functional EP4
receptor agonist, is efficacious in a rat model of acute renal
failure, whereas both EP2 and EP4 receptor agonism prevents
the progression of chronic renal failure.
RESULTS
EP2 and EP4 receptor agonists
We hypothesized that specific PGE2 receptor subtype agonists
(Table 1) would have a positive impact on renal damage in
the rat and be devoid of severe side effects of PGE2. To test
our hypothesis, we sought EP2, EP4, and EP2/4 receptor-
selective agonists. CP-043,305-02, CP-044,519-02, and CP-
536,745-01 bound with high affinity and were selective and
potent full agonists of the EP receptor, as measured by their
ability to increase intracellular cAMP levels to the same levels
as treatment with PGE2 (Table 1).
Mercury chloride model of acute renal failure
Serum creatinine (Cr) values of control rats increased 7.5-
fold on day 1 and 3 following HgCl2 injection (Figure 1a). In
rats treated with 10 mg/kg of an EP4 (CP-044,519-02)
receptor agonist, Cr values were significantly lower on days
1–3 (Figure 1a). A dose of 1 mg/kg EP4 receptor agonist was
less effective, showing a statistical significance only on day 2
following mercury chloride (HgCl2) injection. At 6 days after
HgCl2 application, there were no differences between
treatment groups due to the low survival rate of control
animals (Figure 1a). Dynamic changes of blood urea nitrogen
showed a similar trend as serum Cr value. Animals treated
with 10 mg/kg of EP4 had lower blood urea nitrogen on days
1 and 2 as compared to control animals, whereas rats treated
with 1 mg/kg had lower values only on day 1 (data not
shown). Therapy with the EP2 (CP-536,745-01) and EP2/4
(CP-043,305-02) receptor agonist had no effect on serum Cr
values (Figure 1b and c). At termination on day 6 following
HgCl2 administration, 90–95% of rats treated with both 1
and 10 mg/kg EP4 survived, whereas 85% of the rats treated
with EP2 survived (Figure 1b). About 73% of rats survived
in the group treated with 10 mg/kg of EP2/4 receptor agonist,
whereas 1 mg/kg EP2/4 was ineffective (Figure 1c). On the
contrary, only 40% vehicle-treated control rats survived at
day 6 following HgCl2 injection (Figure 1).
Based on the functional remnant kidney parameters, we
next analyzed the effect of the EP4 receptor agonist on the
renal histopathology and apoptosis. The cellular necrosis
of the proximal tubules was moderate in the EP4 receptor
agonist-treated rats, whereas EP2 and EP2/4 receptor agonists
were less effective or had no effect (Table 2). However, no
histopathological changes were found in the glomeruli
(Figure 2). There was a lower number of apoptotic cells in
the kidneys treated with the EP4 receptor agonist at the
termination of the experiment, suggesting that apoptosis is
an important event in the nephrotoxic kidney damage and
that prevention and recovery are best pronounced in the EP4
receptor agonist-treated rats (Table 3). These results suggest
that EP4 receptor agonism had an effect on the biochemical
renal serum parameters, correlated with significantly im-
proved histopathological findings as compared to similar
analyses of kidney sections treated with EP2 and EP2/4
receptor agonists (Tables 2 and 3).
Table 1 | PGE2 receptor subtype agonists
EP2 EC50 (nM) EP4 EC50 (nM)
CP-536,745-01 (EP2) 1.2
CP-043,305-02 (EP2/4) 384 8.6
CP-044,519-02 (EP4) 2.5
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5/6 nephrectomy model of chronic renal failure
Serum Cr concentrations increased 70% in Nx animals
throughout the duration of the experiment (Figure 3). In
contrast, animals receiving EP4, EP2, and EP2/4 receptor
agonists once a week had lower serum Cr values at 9 and 11
weeks following the beginning of therapy (Figure 3a). In an
another experiment, Nx rats injected with EP4 receptor
agonist three times a week had lower serum Cr values 8 and
11 weeks following the beginning of therapy (Figure 3b), and
did not show serious side effects that include diarrhea,
lethargy, and increased body temperature. Both, 1 and/or 3
weekly administrations of EP4 receptor agonist were equally
effective in delaying the progression of the disease (Figure
3b). GFR was 41% higher at 8 weeks following the beginning
of therapy in rats receiving the EP4 receptor agonist three
times a week, whereas animals dosed once weekly had GFR
increased 45%, 11 weeks following treatment (Table 4).
EP4 receptor agonist-treated rats had reduced glomerular
sclerosis, more viable glomeruli, less tubulointerstitial injury,
and better preservation of proximal and distal tubule
structures as compared to control Nx rats (Table 5, Figure 4).
Similar histopathologic prevention of the progression of
kidney damage was detected in animals treated with EP2
and EP2/4 receptor agonists (data not shown). The immuno-
histochemical analysis of peritubular capillary-derived
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Figure 1 | Therapeutic effect of (a) CP-044,519-02 (EP4), (b) CP-536,745-01 (EP2), and (c) CP-043,305-02 (EP2/4) on serum Cr and
survival in the HgCl2 nephrotoxic rat model. EP4 receptor agonist decreased serum Cr and increased the survival rate. EP2 and EP2/4
receptor agonists had no effect on serum Cr values; EP2 increased the survival rate; only the dose of 10 mg/kg EP2/4 increased the survival.
Results are mean7s.e.m. of 10 rats per treatment group. *Po0.05 with respect to HgCl2-control rats. Moribund rats were killed to prevent
suffering (see Materials and Methods).
Table 2 | Proximal tubular necrosis in HgCl2 control,
CP-044,519-02 (EP4)-, CP-536,745-01 (EP2)-, and CP-043,
305-02 (EP2/4)-treated rats
Treatment groups
Scores for the severity of
necrosis in proximal tubules
Control vehicle 9.270.64
CP-044,519-02 (1 mg/kg) 4.670.31*
CP-044,519-02 (10 mg/kg) 3.970.26*
CP-536,745-01 (1 mg/kg) 8.170.92
CP-536,745-01 (10 mg/kg) 6.970.42
CP-043,305-02 (1 mg/kg) 10.972.4
CP-043,305-02 (10 mg/kg) 6.370.72
Results are mean7s.e.m. of 10 kidneys (three sections each) per treatment group.
*Po0.05 with respect to HgCl2-control rats.
a b
Figure 2 | Effect of CP-044,519-02 (EP4) on renal histology
(periodic acid-Schiff stain) in rats subjected to HgCl2 injection.
The cellular necrosis of the proximal tubules was decreased in the
EP4 receptor agonist-treated rats and no histopathological changes
were found in the glomeruli. Comparison of typical histology from
animals treated with vehicle (a, original magnification  25) or
CP-044,519-02 (b, original magnification  25) at day 6 of therapy.
Table 3 | Effect of CP-044,519-02 (EP4), CP-536,745-01 (EP2),
and CP-043,305-02 (EP2/4) on apoptosis in rats with ARF
Treatment groups Number of apoptotic cells per slice
Control 13877568
CP-044,519-02 (1 mg/kg) 8957322*
CP-044,519-02 (10 mg/kg) 7467214*
CP-536,745-01 (1 mg/kg) 14807506
CP-536,745-01 (10 mg/kg) 11207301
CP-043,305-02 (1 mg/kg) 13507240
CP-043,305-02 (10 mg/kg) 8897112*
Results are mean7s.e.m. of 10 kidneys (three sections each) per treatment group.
*Po0.05 with respect to HgCl2-control rats.
Abbreviation: ARF, acute renal failure.
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smooth muscle cells revealed that approximately fourfold
more cells in EP4-treated kidneys expressed smooth muscle
a-actin, suggesting that EP4 receptor agonist supports the
maintenance of a vascular smooth muscle cell phenotype
(Figure 5a and b).
Cell proliferation evaluated by proliferating cell nuclear
antigen (PCNA) staining indicated an increase in the proxi-
mal tubule cell proliferation in EP4 receptor agonist-treated
rats (Figure 5c and d). EP4 also attenuated the expression of
intracellular adhesion molecule-1, an important molecule
mediating the progress and intensity of renal necrosis and
subsequent fibrosis (Figure 5e and f). Mac CD 68 staining
detected an accumulation of macrophages in vehicle-treated
rats. In contrast, rats treated with EP4 receptor agonist had
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Figure 3 | Therapeutic effect of 1 mg/kg of CP-044,519-02 (EP4),
CP-536,745-01 (EP2), and CP-043,305-02 (EP2/4) once a week and
CP-044,519-02 (EP4) once and three times a week on serum Cr in
a 5/6 Nx rat model of chronic renal failure. (a) All three receptor
agonists were effective in reducing serum Cr values of Nx rats 9 and
11 weeks following Nx. (b) Both, 1 and/or 3 weekly administrations
of EP4 receptor agonist were equally effective in delaying the
progression of the disease. Results are presented as mean7s.e.m.
of (a) 25 rats per treatment group in and (b) 12 rats per treatment
groups in. *Po0.05 vs control; **Po0.005 vs control. 2/3 Nx and 5/6
Nx indicates surgical nephrectomies as described in Materials and
Methods; Th indicates the beginning of therapy.
Table 4 | Effect of CP-044,519-02 (EP4) on GFR (ml/min/g)
in rats with CRF
GFR (ml/min/g)
Weeks of therapy
Therapy 2 5 8 11
Control
vehicle
0.5570.23 0.6270.23 0.5070.16 0.3570.10
CP-044,519-02
(10mg/kg)
3 /week
0.5170.16 0.6870.16 0.8570.41a 0.6370.37a
CP-044,519-02
(10 mg/kg)
1 /week
0.5070.19 0.5570.10 0.5770.30 0.6470.43a
Results are mean7s.e.m. of 10 rats per treatment group.
*Po0.05 with respect to Nx-control rats.
Abbreviations: GFR, glomerular filtration rate; Nx, nephrectomy.
Table 5 | Morphological lesions of Nx control and CP-044,
519-02 (EP4)-treated rats in CRF
Group
CP-044,519-02 CP-044,519-02
Vehicle 1 /week 3 /week
Tubulointerstitium 2.8270.23 1.3670.30b 1.0070.28b
Tubular dilatation/athrophy 3.070.28 1.2570.30b 1.0070.32b
Interstitial fibrosis 2.3370.33 1.2570.30a 1.2070.26a
Inflammatory cells 2.6770.38 1.5070.18a 1.0070.22a
Glomeruli 2.8270.19 1.1470.33b 0.8270.19b
Glommerular sclerosis 2.6770.38 1.2570.16a 0.8070.14a
Microaneurysms 2.0070.48 0.7570.30 0.6070.17a
Absence of viable glomeruli 2.3370.32 1.0070.37a 0.6070.04a
Morphological lesions were quantified as described in the Materials and Methods
section. Two independent observers without significant over- or underestimation
between them analyzed kidneys of 12 animals per treatment group. The results are
presented as mean7s.e.m. of 10 kidneys (three sections each) per treatment group.
aPo0.05, bPo0.005 with respect to Nx-control rats.
Abbreviation: Nx, nephrectomy.
a b
c d
Figure 4 | Effect of CP-044,519-02 (EP4) on renal histology
(hematoxylin and eosin) in rats subjected to 5/6 Nx. EP4 receptor
agonist-treated rats had reduced glomerular sclerosis, more viable
glomeruli, less tubulointerstitial injury, and better preservation of
proximal and distal tubule structures as compared to control Nx rats.
A typical histology from animals treated with a vehicle (original
magnifications: a,  12.5; c,  50) or CP-044,519-02 (b,  12.5,
d  50) at 11 weeks of therapy.
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approximately ninefold less macrophages accumulated in the
remaining kidney parenchyme (Figure 5g and h).
EP2 and EP4 receptor expression
The effect of EP4, EP2, and EP2/4 receptor agonists on EP2
and EP4 mRNA was evaluated by real-time polymerase chain
reaction in kidneys of 5/6 Nx control rats (Figure 6a) and in
those treated with all three PGE2 receptor agonists. Following
nephrectomy (Nx), the EP2 receptor expression was reduced
by 50% as compared to sham animals, however, treatment
with the EP2/4 receptor agonist brought the EP2 expression
levels back to sham values (Figure 6a). EP4 expression level
did not change following Nx and treatment with EP2/4 had a
slight effect on the EP4 gene expression (Figure 6a). At the
end of the therapy, there was a slight elevation in EP2 and EP
4 receptor expression in rats treated with all three PGE2
receptor agonists as compared to sham animals (Figure 6b).
DISCUSSION
PGE2 is ubiquitously present in animals and humans and
has potent responses in a number of organ systems. Data in
pre-clinical animal models and humans suggest that PGE2
plays a crucial role in normal as well as pathological renal
function.19–25 The present study indicates that CP-044,
519-02, a selective agonist of the PGE2 EP4 receptor, reduces
nephrotoxic injury and increases the survival rate of animals
with ARF. Biochemical serum parameters indicate that
systemically administered EP4 receptor agonist limits the
extent of injury and/or speeds up the recovery of injured
tubular cells. The same trends of both parameters strongly
indicate the beneficial effect of the EP4 receptor agonist in
the HgCl2-caused kidney damage. HgCl2 exerts its toxic
effects on kidney cells through a variety of mechanisms, with
the principal target being the S3 segment of the proximal
tubules. It interferes with respiratory chain and oxidative
phosphorylation enzymes26–28 and causes oxidative injury
with subsequent lipid peroxidation, DNA damage, and
protein oxidation.29 The EP4 receptor agonist reduced the
number of apoptotic cells in the kidney and its cytoprotective
action was responsible for the rapid regeneration of the renal
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Figure 5 | Immunohistochemical staining of smooth muscle
a-actin, proliferating cell nuclear antigen, intercellular cell
adhesion molecule, and macrophage-associated antigen CD
68. Comparison of (a, b) smooth muscle a-actin, (c, d) PCNA, (e, f)
intracellular adhesion molecule and (g, h) Mac staining of (a, c, e, g)
vehicle and (b, d, f, h) CP-044,519-02-treated kidneys at 11 weeks of
therapy. Fourfold more cells in EP4-treated kidneys expressed
smooth muscle a-actin, maintaining vascular smooth muscle cell
phenotype. Cell proliferation evaluated by PCNA staining indicated
an increase in proximal tubule cell proliferation in EP4 receptor
agonist-treated rats. EP4 also attenuated the expression of intra-
cellular adhesion molecule -1, mediating renal fibrosis. Mac CD 68
staining detected ninefold less macrophages accumulated in the
remaining kidney parenchyme of rats treated with the EP4 receptor
agonist. Original magnification 12.5.
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Figure 6 | EP2 and EP4 receptors expression during the therapy
in the kidneys of 5/6 Nx rats treated with CP-043,305-02 (EP2/4)
(a), and the end of the therapy in the kidneys of 5/6 Nx rats
treated with CP-044,519-02 (EP4), CP-536,745-01 (EP2), and
CP-043,305-22 (EP2/4). Following Nx, the EP2 receptor expression
was reduced by 50% (0.5-fold change) as compared to sham animals
(Po0.05). Treatment with the EP2/4 receptor agonist brought the
EP2 expression levels back to sham values (a). EP4 expression level
did not change following Nx and treatment with EP2/4 had a slight
effect on the EP4 gene expression as compared to sham animals
(a). At the end of the therapy, there was a slight elevation in EP2 and
EP4 receptor expression in rats treated with all three PGE2 receptor
agonists as compared to sham animals (b). All data are represented as
fold change to gene expression of sham animals7s.e.m. (represented
by 1.0 on the y-axis).
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function. More than 90% of rats survived in the EP4 receptor
agonist-treated group, in comparison to 40% in the control
group, indicating that the EP4 receptor agonist reduced the
severity of ARF and, therefore, could potentially be beneficial
in treating ARF. As both the EP2 and EP2/4 receptor agonists
had no influence on serum biochemical parameters and the
EP2 receptor agonist did not improve the survival of rats
with ARF, we suggest that the EP4 receptor is essential for the
prevention and/or restoration of the kidney structure and
function in ARF. On the contrary, in a model of CRF, all three
tested molecules were effective in preserving kidney func-
tion suggesting that both EP2 and EP4 receptor agonism
is capable of preventing progressive deterioration of the
remnant glomerular function in this rat model. CRF is
associated with reduction of GFR, elevated serum Cr values,
glomerulosclerosis, and tubulointerstitial injury. These are
reproduced in the rat remnant kidney model of CRF, where
the initial compensatory renal growth response to reduction
of the parenchyme is followed in the long term by a
progressive renal scarring. Typically, the late renal fibrotic
changes are associated with the progressive loss of glomerular
cells, tubular atrophy, and their replacement by fibrous
tissue.30
EP receptors have been shown to be expressed in various
kidney cells including mesangial cells.31 Recently, the role of
the EP1 receptor in nephropathy using receptor-specific
small molecule inhibitors has been demonstrated.18 It was
suggested that selective inhibition of the EP1 receptor
inhibits glomerular hypertrophy and proteinuria, TGF-beta
and fibronectin transcriptional activation, preventing the
development of diabetic renal injury in rats.18
Here, we show in pre-clinical models with impaired renal
function that the expression of the EP2 and the EP4 receptor
is not significantly regulated at a message level. Interestingly,
EP4 receptor agonist is more effective in ARF, whereas
EP2, EP4, and EP2/4 receptor agonism is both effective in
preventing the progression of the chronic renal failure. Thus,
it is suggested that both EP2 and EP4 receptors play a major
role in regulating the kidney function. Following Nx, the
expression of the EP4 receptor remains similar to sham rats,
whereas the expression of the EP2 receptor is downregulated
and then upregulated at week 9 following therapy with all
three receptor agonists.
Prostaglandins and in particular PGE2 in the normal
kidney physiology regulate vascular smooth muscles, GFR,
the release of salt, water re-absorption, and the release of
renal hormones.32 Our results indicate that a role for PGE2
signaling via the EP2 and EP4 receptor in kidney may be
more critical than has been recognized to date. The observed
cytoprotection against glomerular degeneration, the preser-
vation of proximal and distal tubule structures, and the
presence of newly formed nephrogenic structures seen in EP2
and EP4 receptor agonist-treated kidneys suggest that PGE2
signaling via the EP2 and EP4 receptor may provide a
morphogenic signal for the repair and regeneration of
postnatal renal tissue in both the acute and chronic renal
failure. PGE2 is, therefore, not involved only in regulating
renal functions but it also has an important role in the repair
of damaged renal tissue or in protecting renal tissue against
insult and injury.
As the process of the chronic kidney failure in humans
occurs over years, delaying the progression is critical for the
treatment of chronic kidney diseases. Selective agonists of the
EP4 and/or the EP2 receptor, thus, may be used to improve
renal architecture during the course of renal disease and
recover the lost renal function.
MATERIALS AND METHODS
Screening for PGE2 selective agonists
Compounds were categorized based on their ability to bind various
prostanoid receptors and all three molecules were selective agonists
when measured against other PGE2 receptors such as prostaglandin I
(IP) and prostaglandin D (DP) (Paralkar et al.,33data not shown).
EP2 and EP4 receptor agonism was further defined by the ability of
compounds to increase intracellular cAMP levels in human
embryonic kidney-293 cells overexpressing either the EP2 or the
EP4 receptor. cAMP was quantitated using a radioimmunoassay kit
according to the manufacturer’s instructions (DuPont/NEN Re-
search Products, Boston, MA, USA).
HgCl2 model of ARF
Wistar male rats of 240–250 g were maintained in acclimatized cages
on a 12 h light–dark cycle and had free access to standard laboratory
chow and tap water. The nephrotoxin (mercury chloride, HgCl2,
2.5 mg/kg) was administered subcutaneously (s.c.) in a bolus upon
basal serum biochemistry values and animals were randomly
assigned to one of seven groups: (1) HgCl2 control (n¼ 10);
(2) HgCl2þCP-043,305-02 (1 mg/kg, n¼ 10); (3) HgCl2þCP-043,
305-22 (10 mg/kg, n¼ 10); (4) HgCl2þCP-044,519-02 (1 mg/kg,
n¼ 10); (5) HgCl2þCP-044,519-02 (10 mg/kg, n¼ 10); (6)
HgCl2þCP-536,745-01 (1 mg/kg, n¼ 10); and (7) HgCl2þCP-
536,745-01 (10 mg/kg, n¼ 10). The compound was administered
10 min after HgCl2 injection and continued at 24-h intervals until
termination. Control animals received the same volume of vehicle
buffer (beta-c-dextran) at the same time points. Animal models
were approved by the Institutional Scientific Board.34
5/6 nephrectomy model of CRF
Male Wistar rats weighing approximately 400 g were fed standard
rat chow ad libitum and were given free access to water. A total of
36 animals underwent 5/6 nephrectomy (5/6 Nx).35 The study follo-
wed the previously published protocol.36 Animals were subjected to
unilateral 2/3 nephrectomy (left kidney) under ketamin/diazepam
anesthesia (100 or 2.5mg/kg, respectively). After 2 weeks, the right
kidney was surgically removed under anesthesia.13 In the first
experiment, 5/6 Nx rats were randomly assigned into five groups:
(1) Sham operated (n¼ 5); (2) Nx-control (n¼ 12); (3) NxþCP-
536,745-01 (10 mg/kg, 1 /week; n¼ 25); (4) NxþCP-043,305-02
(10 mg/kg, 1 /week; n¼ 25); and (5) NxþCP-044,519-02 (10 mg/
kg, 1 /week; n¼ 25). At 2 weeks following the second operation,
CP-536,745-01, CP-043,305-02, or CP-044,519-02 were dissolved in
beta-c-dextran and administered via the rat tail vein once a week
throughout the period of 11 weeks. Control animals received only
beta-c-dextran as a vehicle. Animals were killed 11 weeks following
Nx by overdose of sodium pentobarbital. In the second experiment,
5/6 Nx rats were randomly assigned into three groups: (1) Nx-
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control (n¼ 12); (2) NxþCP-044,519-02 (10 mg/kg, 1 /week;
n¼ 12); and (3) NxþCP-044,519-02 (10 mg/kg, 3 /week; n¼ 12).
Two weeks following the second operation, CP-044,519-02 was
dissolved in beta-c-dextran administered via the rat tail vein once or
three times a week throughout the period of 11 weeks. Control
animals received only beta-c-dextran as a vehicle. Animals were
killed 11 weeks following Nx by overdose of sodium pentobarbital.
RNA isolation and gene expression analysis by real-time
polymerase chain reaction
Total RNA was isolated from kidneys of sham-operated rats and rats
receiving CP-536,745-01, CP-043,305-22, or CP-044,519-02 at 0, 2,
5, 7, and 9 weeks following 5/6 Nx and relative quantification of
gene expression was carried out as previously described.37,38 Beta-
actin was chosen as the most stable housekeeping gene for the CP-
043,305-02- and CP-044,519-02-treated kidneys and glyceraldehyde-
3-phosphate dehydrogenase for the CP-536,745-01 therapy. The
following gene-specific primers were used: forward GTG CTG GTA
ACG GAA CTG GT and reverse CGT GGC CAG ACT AAA GAA GG
for EP2; forward ACA CCA CCT CGC TGA GAA CT and reverse
GCT CCC ACT AAC CTC ATC CA for EP4; forward CAT CCT GAA
CCG TCT GTG TG and reverse TTT CCA CCA AGG ACC CAC TA
for albumin; forward ATG ATT CTA CCC ACG GCA AG and reverse
CTG GAA GAT GGT GAT GGG TT for glyceraldehyde-3-phosphate
dehydrogenase, and forward GGG AAA TCG TGC GTG ACA TT and
reverse GCG GCA GTG GCC ATC TC for beta-actin.
Renal function
HgCl2 model of ARF. Blood samples (0.5 ml) were obtained
from the orbital venous plexus at 0, 24, 48, 72, and 128 h after HgCl2
administration. Serum creatinine was measured by the Jaffe method
(alkaline picrate) and blood urea nitrogen by enzymatic glutamate
dehydrogenase-UV procedure as previously described in Vukicevic
et al.39 The cumulative survival rate was also observed and recorded
for both control and experimental rats. Animals were killed 6 days
after HgCl2 treatment.
5/6 nephrectomy model of CRF. Blood samples and 24-h urine
collections in metabolic cages were taken on weeks 2, 5, 8, and 11.
Serum and urine creatinine was measured using the standard Jaffe`
method. The GFR was determined using serum creatinine over urine
creatinine as adjusted to body weights.
Histology
HgCl2 model of ARF. At termination, kidneys were removed,
cut longitudinally and one half of each kidney was fixed in 4%
paraformaldehyde, embedded in paraffin, and 4 mm paraffin sections
were cut with a microtome and stained with periodic acid-Schiff
stain. Qualitative and semiquantitative assessments of the level
of necrosis of proximal tubules and other pathological changes
in kidney sections were made blindly using a light microscope.
The level or severity of necrosis in proximal tubules was ranked for
each animal on a scale of 0–12, where 0 represents no cellular
necrosis and 12 represents a level of necrosis that involves virtually
every proximal tubular segment visible in the plane of section as
previously described.40
5/6 nephrectomy model of CRF. Kidneys for histological
examination were fixed in 2% paraformaldehide and 7 mm paraffin
sections were cut and stained with hematoxylin and eosin.
Tubulointerstial injury, defined as tubular dilatation and/or atrophy,
interstitial fibrosis, and inflammatory cell infiltrate, as well as
glomerular damage, were graded using a semiquantitative scale from
0 to 4 according to the following criteria: 0¼ no changes; 1¼ focal
changes involving 1–25% of the sample; 2¼ changes affecting
26–50% of the sample; 3¼ changes involving 51–75% of the sample,
and 4¼ lesions affecting more than 75% of the sample.41 Two
independent observers performed histological studies in a blinded
fashion.
Immunohistochemical analyses. Immunocytochemistry was
performed using the immunoperoxidase detection system (Zymed,
San Francisco, CA, USA). The following monoclonal antibodies
were used: PCNA (DAKO, Copenhagen, Denmark), smooth muscle
a-actin (DAKO), intracellular adhesion molecule (CD 54; DAKO),
and Mac (CD-68) (DAKO). A minimum of 3000 cells was counted
per kidney section stained for PCNA and smooth muscle a-actin,
and the number of positive cells was expressed as a percentage of
total counted cells in subdivisions of cortex, and/or the S3 zone.
Apoptosis
HgCl2 model of ARF. Apoptotic cells were detected by a TACS 2
TdT in situ apoptosis system (Trevigen, Gaithersburg, MD, USA),
which detects double-strand breaks in genomic DNA by enzymatic
incorporation of a biotinylated nucleotide with terminal deoxynu-
cleotidyl transferase followed by binding of streptavidin-horseradish
peroxidase. The modifications of the procedure include labeling
time of 90 min, coverslips in all reactions to prevent drying of
samples, and incubation time of streptavidin–HRP of 15 min.42
Statistical analysis
All data are presented as mean7s.e.m. One-way analysis of variance
was performed to determine the effect of treatment on biochemical
parameters. Student t-test was used to determine the effect of
therapy on the gene expression level as compared to sham animals.
Statistical evaluation of the survival rate was carried out by the Peto¨-
Wilcoxon test, and results were considered significant when the
probability of error (P) was o0.05.
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